A Phase III Study of Subconjunctival Human Anti–Transforming Growth Factor β2 Monoclonal Antibody (CAT-152) to Prevent Scarring after First-Time Trabeculectomy
- 31 October 2007
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 114 (10), 1822-1830.e2
- https://doi.org/10.1016/j.ophtha.2007.03.050
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The Effect of the Timing of Scleral Flap Suture Release on the Safety and Long-term Success of PhacotrabeculectomyAmerican Journal of Ophthalmology, 2006
- Involvement of CTGF in TGF-β1–Stimulation of Myofibroblast Differentiation and Collagen Matrix Contraction in the Presence of Mechanical StressInvestigative Ophthalmology & Visual Science, 2004
- Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil*1Survival analysisOphthalmology, 2004
- Factors associated with success in first-time trabeculectomy for patients at low risk of failure with chronic open-angle glaucomaOphthalmology, 2004
- Evaluation of Anti-TGF-β2 Antibody as a New Postoperative Anti-scarring Agent in Glaucoma SurgeryInvestigative Ophthalmology & Visual Science, 2003
- Human antitransforming growth factor β2 monoclonal antibody—a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical studyOphthalmology, 2002
- The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deteriorationAmerican Journal of Ophthalmology, 2000
- Activation and suppression of fibroblast functionEye, 1994
- Rational choice of therapy in primary open angle glaucomaEye, 1992
- Transforming growth factor-β in human aqueous humorCurrent Eye Research, 1990